Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

wing the conference call.  A telephone replay of the conference call will be available through Thursday, February 18, 2010 by calling 1-800-642-1687 for domestic and +1-706-645-9291 for international.  Please use the pass code 54652678 to access the replay.  

Forward Looking Statements

This document may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and Rule 3b-6 under The Securities Exchange Act of 1934, as amended, including, without limitation, statements regarding expected performance, especially expectations with respect to sales, research and development expenditures, earnings per share, capital expenditures, acquisitions, divestitures, collaborations, or other expansion opportunities.  These statements may be identified by the fact that they use words such as "expects," "anticipates," "intends," "estimates," "believes" or similar expressions in connection with any discussion of future financial and operating performance.  Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout the Company's public filings.  Any forward-looking statements contained herein are based on current plans and expectations and involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations including, but not limited to, global economic trends, pharmaceutical outsourcing trends, competitive pricing or product developments, government legislation and regulations (particularly environmental issues), tax rate, interest rate, technology, manufacturing and legal issues, including the outcome of outstanding litigation disclosed in the Company's public filings, the Company's ability to satisfy the continued listing standards of the New York Stock Exchange, changes in foreign exchange rates,  uncollectible receiv
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... -- TaiGen Biotechnology Company, Limited ("TaiGen") today announced ... R-Pharm, a leading Russian pharmaceutical company, to develop ... Russian Federation , ... Commonwealth Independent States (CIS). Nemonoxacin is a novel antibiotic ... caused by drug-resistant bacteria. Under the terms of ...
(Date:1/14/2014)... January 14, 2014 Carahsoft and ... for Thursday, January 23, 2014 at 2pm EST ... into Actionable Knowledge.” The topic focuses on how ... knowledge to drive mission critical decisions for government ... hour. , Synopsis: Big Data has become an ...
(Date:1/14/2014)... 2014  3D Communications, a leading provider of strategic communications ... business, and media events in the United States ... its former associate Virginia Cox , JD, is returning ... Virginia Cox re-joins 3D after more ... Office of External Affairs at the U.S. Food and Drug ...
(Date:1/14/2014)... New York, NY (PRWEB) January 14, 2014 ... has initiated coverage of Alliqua, Inc. (OTCQB: ALQA). ... manufacturing, and marketing proprietary products to serve the ... http://equitiesiq.com/reports/alliqua/ , In late 2012, Alliqua was ... which launched the company’s new strategy to become ...
Breaking Biology Technology:TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 2TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 3TaiGen Biotechnology Signed Exclusive License Agreement with R-Pharm for Nemonoxacin (Taigexyn(R)) 4Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3
... Scientific,Corporation (NYSE: BSX ) is scheduled to participate ... being held September 10 and 11,in New York City. ... make a,25-minute presentation followed by a 25-minute question and ... a.m. ET. A live webcast of Mr. LaViolette,s ...
... Artery ... Disease - ... -, FREMONT, Calif., Aug. 28 Vermillion, Inc.,(Nasdaq: VRML ), formerly ... called beta-2,microglobulin may aid in the diagnosis of peripheral artery disease (PAD).,The findings, ...
... (Pink Sheets: BIEL), announced today that Astonix Life,Science, ... provide ActiPatch,Therapy to the healthcare market in Singapore. ... ActiPatch to the market has been warmly,received. ... the Healthcare providers,in Singapore has been strong enough ...
Cached Biology Technology:Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 2Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease 3BioElectronics Corporation Announces Singapore and Malaysia Sales 2
(Date:4/14/2014)... of subarctic forest moths in Finnish Lapland suggests that ... on animals and plants because much of the harm ... of 80 moth species and found that 90 percent ... study period, from 1978 to 2009. During that time, ... degrees Fahrenheit, and winter precipitation increased as well. , ...
(Date:4/14/2014)... climate over the past three decades have caused small ... national animal. UCLA biologists have found that not only ... has also become shorter and higher pitched. ... integrative biology and physiology and of ecology and evolutionary ... study examined 170 male coqui frogs ( Eleutherodactylus coqui ...
(Date:4/14/2014)... ( http://www.ucr.edu ) David Kisailus, the Winston ... University of California, Riverside,s Bourns College of Engineering, ... Fellows are young scientists selected by the advisory ... National Academy of Sciences and organizers of the ... series. The Kavli Foundation, which is based in ...
Breaking Biology News(10 mins):Moth study suggests hidden climate change impacts 2Moth study suggests hidden climate change impacts 3Climate change a likely culprit in coqui frog's altered calls, say UCLA biologists 2Professor receives young scientist honor 2
... permanently damaged their skin cells, causing them to overproduce ... uneven skin tone over time. But new research indicates ... arthritis ?can actually help stop the formation of new ... findings on glucosamine may impact the way dermatologists treat ...
... warm, sun-drenched, tropical seas; some species are found at ... waters throughout the world's oceans. Some cold-water coral reefs ... a diversity rivaling some better known tropical coral reefs. ... method in which vessels drag large, heavily weighted nets ...
... the rewarding effect of cocaine on mice by genetically ... animal's brain. , While the researchers aren't suggesting that ... brings to light the key protein that controls cocaine's ... medications that achieve the same results and therefore help ...
Cached Biology News:Science finds new fix for UV-damaged skin in arthritis treatment 2Science finds new fix for UV-damaged skin in arthritis treatment 3Ocean acidification threatens cold-water coral ecosystems 2Genetically altered mice no longer like cocaine 2Genetically altered mice no longer like cocaine 3
... GeneBLAzer cell-based assays utilize the ... of the negatively charged fluorescent beta-lactamase ... esters readily enter the cell, where ... converts them into their negatively charged ...
... GeneBLAzer cell-based assays utilize the membrane-permeant ... the negatively charged fluorescent beta-lactamase substrates, ... readily enter the cell, where cleavage ... them into their negatively charged forms, ...
1M stock solution (238mg/ml)...
Request Info...
Biology Products: